SCHEMBL3308089

SCHEMBL3308089

Cc1ccccc1-n1nc(C(F)(F)F)cc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
MAPT P10636 2/20 0.55
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
PTGS1 P23219 3/20 0.45
PTGS2 P35354 3/20 0.45
NR3C1 P04150 1/20 0.45
PGR P06401 1/20 0.45
NR3C2 P08235 1/20 0.45
KDM4E B2RXH2 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
CYP1A2 P05177 2/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
TP53 P04637 1/20 0.38
RXRA P19793 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1013289 0.86 ALDH1A1 (0.56) ALDH1A1MAPTHTTKMT2AKDM4E
Hydrochloric Acid SCHEMBL1492473 0.84 ALDH1A1 (0.55) ALDH1A1MAPTHTTKMT2AKDM4E
SCHEMBL13105360 0.84 MAPT (0.52) ALDH1A1MAPTPTGS1PTGS2NR3C1
SCHEMBL2257225 0.83 RXRA (0.46) ALDH1A1MAPTKMT2APTGS1PTGS2
SCHEMBL6676733 0.81 RXRA (0.50) PTGS1PTGS2NR3C2KDM4EL3MBTL1
SCHEMBL15478690 0.81 NR3C1 (0.45) ALDH1A1MAPTHTTKMT2APTGS1
SCHEMBL16794534 0.81 PTGS2 (0.48) ALDH1A1MAPTPTGS1PTGS2MAPK14
SCHEMBL12859437 0.80 MAPK14 (0.45) ALDH1A1MAPTKMT2APTGS1PTGS2
SCHEMBL12871472 0.79 NR3C2 (0.43) ALDH1A1MAPTHTTKMT2APTGS1
SCHEMBL27826528 0.79 F10 (0.46) PTGS1PTGS2NR3C2KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-22 US disclosed
WO-2010020363-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099681-A1 SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF CYP3A5, ABAT, TPMT ALDH1A1 260/4885MAPT 2724/4885HTT 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.